Rocket Pharmaceuticals (RCKT) Interest Expenses (2014 - 2026)

Rocket Pharmaceuticals (RCKT) has 13 years of Interest Expenses data on file, last reported at $473000.0 in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses changed 0.21% year-over-year to $473000.0; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (changed 0.21% YoY), and the FY2025 full-year result was $133.1 million, up 3.11% from the prior year.
• Interest Expenses held at $473000.0 in Q1 2026, from $473000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $127.1 million in Q3 2023 to a low of $467000.0 in Q4 2022.
• A 5-year average of $40.6 million and a median of $473000.0 in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses sank 99.63% in 2024 and jumped 10058.6% in 2025, its largest moves.
• Tracing RCKT's Interest Expenses over 5 years: stood at $467000.0 in 2022, then advanced by 0.64% to $470000.0 in 2023, then gained by 0.64% to $473000.0 in 2024, then changed by 0.0% to $473000.0 in 2025, then changed by 0.0% to $473000.0 in 2026.
• Business Quant data shows RCKT's Interest Expenses at $473000.0 in Q1 2026, $473000.0 in Q4 2025, and $47.4 million in Q3 2025.